Skip to main content
OpenTrials
Completed

NCT Number: NCT00231114

Asthma Intervention Research 2 (AIR2) Trial

The objective of this randomized, double blind, sham-controlled study is to demonstrate the safety and effectiveness of the Alair System in a population of subjects with severe asthma who are still symptomatic despite being managed on conventional therapy of high doses of inhaled corticosteroids and long-acting β2-agonists.

The primary efficacy endpoint will be the difference between Study groups in the change in Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from the 6-, 9-, and 12-month follow-up visits.

All other outcome measures assessed at 12 months post-treatment.

This will be a multicenter, randomized, double-blind, sham-controlled study comparing the effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA).

A Bayesian adaptive approach to sample size selection is used with a randomization scheme of 2:1 (two Alair Group Subjects for every one Control Group Subject).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

John Hunter Hospital, New Lambton Heights, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is an adult between the ages of 18 to 65 years.
  • Subject has asthma and is taking regular maintenance medication that includes Inhaled corticosteroid (ICS) AND long acting ß2-agonist (LABA).
  • Subject has a Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of greater than or equal to 60% of predicted after medication stabilization during the Baseline Period.
  • Subject has a PC20 < 8 mg/ml per methacholine inhalation test using standardized methods. PC20 is a provocative concentration of Provocholine® (a brand of methacholine chloride) resulting in a drop of FEV1 of 20% or more from Baseline.
  • Subject has at least two days of asthma symptoms during the 4-weeks of the Baseline Diary Period.
  • Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack years total smoking history).

Exclusion criteria

  • Subject has a Post-bronchodilator FEV1 of less than 65%.
  • Subject has 3 or more hospitalizations for exacerbations of asthma in the previous year; OR a history of life-threatening asthma, defined by past intubations for asthma, or ICU admission for asthma within the prior 24 months.
  • Subject has a history of recurrent lower respiratory tract infections requiring antibiotics (more than 3 in the past 12 months).
  • Subject has a history of recurrent oral steroid use for asthma (4 or more pulses of oral steroids in the past 12 months).
  • Subject has a known sensitivity to medications required to perform bronchoscopy (such as lidocaine, atropine and benzodiazepines).
  • Subject has known systemic hypersensitivity or contraindication to Methacholine chloride or other parasympathomimetic agents.
  • Subject has other medical criteria.

Treatment and study plan

Alair System

Device

Treatment of airways with the Alair System

Primary outcomes

  1. Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the "Integrated AQLQ Score."

Secondary outcomes

  1. Percent Symptom-Free Days (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime.

  2. Total Symptom Score (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control.

  3. Number of Puffs of Rescue Medication Used (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.

  4. Percent Days Rescue Medication Used (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.

  5. Asthma Control Questionnaire (ACQ) Score (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient's FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control.

  6. Morning Peak Expiratory Flow (amPEF) (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air.

  7. Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.

  8. Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)

    Time frame: Baseline, 12 Months

    Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.

Other outcomes

  1. Rate of Severe Exacerbations Requiring Systemic Corticosteroids

    Time frame: Baseline, 12 Months

    Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.

  2. Percentage of Subjects With Severe Exacerbations Requiring Systemic Corticosteroids

    Time frame: Baseline, 12 Months

    Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry.

  3. Days Lost From Work/School/Other Activities Due to Asthma

    Time frame: 12 Months

  4. Unscheduled Physician Office Visits for Respiratory Symptoms

    Time frame: 12 Months

  5. Emergency Room Visits for Respiratory Symptoms

    Time frame: 12 Months

  6. Hospitalizations for Respiratory Symptoms

    Time frame: 12 Months

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)

Important dates

Study start
2005
Primary completion
2008
Study completion
2013
First posted
Oct 4, 2005
Registry last updated
Jul 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.